Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8GS6

Structure of the SARS-CoV-2 BA.2.75 spike glycoprotein (closed state 1)

Summary for 8GS6
Entry DOI10.2210/pdb8gs6/pdb
EMDB information34221
DescriptorSpike glycoprotein, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose (3 entities in total)
Functional Keywordsspike glycoprotein, viral protein
Biological sourceSevere acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2)
Total number of polymer chains3
Total formula weight423976.81
Authors
Anraku, Y.,Tabata-Sasaki, K.,Kita, S.,Fukuhara, H.,Maenaka, K.,Hashiguchi, T. (deposition date: 2022-09-05, release date: 2022-10-26, Last modification date: 2024-10-16)
Primary citationSaito, A.,Tamura, T.,Zahradnik, J.,Deguchi, S.,Tabata, K.,Anraku, Y.,Kimura, I.,Ito, J.,Yamasoba, D.,Nasser, H.,Toyoda, M.,Nagata, K.,Uriu, K.,Kosugi, Y.,Fujita, S.,Shofa, M.,Monira Begum, M.,Shimizu, R.,Oda, Y.,Suzuki, R.,Ito, H.,Nao, N.,Wang, L.,Tsuda, M.,Yoshimatsu, K.,Kuramochi, J.,Kita, S.,Sasaki-Tabata, K.,Fukuhara, H.,Maenaka, K.,Yamamoto, Y.,Nagamoto, T.,Asakura, H.,Nagashima, M.,Sadamasu, K.,Yoshimura, K.,Ueno, T.,Schreiber, G.,Takaori-Kondo, A.,Shirakawa, K.,Sawa, H.,Irie, T.,Hashiguchi, T.,Takayama, K.,Matsuno, K.,Tanaka, S.,Ikeda, T.,Fukuhara, T.,Sato, K.
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant.
Cell Host Microbe, 30:1540-1555.e15, 2022
Cited by
PubMed Abstract: The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency, but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.
PubMed: 36272413
DOI: 10.1016/j.chom.2022.10.003
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (2.86 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon